A Chief Scientific Officer Of Humanigen Inc. (HGEN) Buys 0.55 million Shares


Humanigen Inc. (NASDAQ:HGEN) saw a downside of -1.20% to close Tuesday at $0.15 after subtracting $0.0 on the day. The 5-day average trading volume is 2,043,940 shares of the company’s common stock. It has gained $0.1700 in the past week and touched a new high 1 time within the past 5 days. An average of 4,504,955 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,772,402.

HGEN’s 1-month performance is 46.59% or $0.0383 on its low of $0.0924 reached on 12/29/22. The company’s shares have touched a 52-week low of $0.09 and high of $4.11, with the stock’s rally to the 52-week high happening on 01/04/23. YTD, HGEN has achieved 23.50% or $0.0282 and has reached a new high 2 times. However, the current price is down -96.39% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

HGEN stock has a beta of -0.99. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.07.

Humanigen Inc.’s quick ratio for the period ended June 29 was 0.30, with the current ratio over the same period at 0.30. The firm’s gross profit as reported stood at $236.37 million against revenue of $3.6 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -181.72% to -$23.69 million, while revenue of -$30.15 million was -27.27% off the previous quarter. Analysts expected HGEN to announce -$0.3 per share in earnings in its latest quarter, but it posted -$0.43, representing a -43.30% surprise. EBITDA for the quarter stood at more than -$22.72 million. HGEN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 78.37 million, with total debt at $25.39 million. Shareholders hold equity totaling $119.08 million.

Let’s look briefly at Humanigen Inc. (HGEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 48.19% to suggest the stock is trending Neutral, with historical volatility in this time period at 74.57%.

The stock’s 5-day moving average is $0.1513, reflecting a -10.72% or -$0.0178 change from its current price. HGEN is currently trading +47.32% above its 20-day SMA, -34.13% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +12.53% and SMA200 by-95.19%.

Stochastic %K and %D was 47.57% and 52.95% and the average true range (ATR) pointed at 0.0166. The RSI (14) points at 50.69%, while the 14-day stochastic is at 37.60% with the period’s ATR at 0.0167. The stock’s 9-day MACD Oscillator is pointing at -0.0077 and -0.0115 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Humanigen Inc. (NASDAQ: HGEN), ROTH Capital downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for HGEN stock have a consensus rating for the stock as Underweight. Currently, 1 brokerage advisors rate HGEN as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.


Please enter your comment!
Please enter your name here